The second peat ot tne aosorpuon curves observed in the group 3 patients ( fig. 3 ) is probably explained by "biliary recycling." This observation was unexpected and therefore not studied under ideally controlled circumstances with standardized meals and at standardized time after digoxin administration. But the evidence is striking all the same. It may indicate that the drug is excreted in the bile and reabsorbed when food is given. Another explanation is that the bile enhances the absorption of the drug present in the bowel. White et al. (1971) found that the absorption of digoxin was reduced when the drug was given after food. It is therefore unlikely that the food by itself inceased the absorption and gave the second peak observed.
The second peat ot tne aosorpuon curves observed in the group 3 patients ( fig. 3 ) is probably explained by "biliary recycling." This observation was unexpected and therefore not studied under ideally controlled circumstances with standardized meals and at standardized time after digoxin administration. But the evidence is striking all the same. It may indicate that the drug is excreted in the bile and reabsorbed when food is given. Another explanation is that the bile enhances the absorption of the drug present in the bowel. White et al. (1971) found that the absorption of digoxin was reduced when the drug was given after food. It is therefore unlikely that the food by itself inceased the absorption and gave the second peak observed.
When the same maintenance dose of L 1 and L 2 was given, there was a little difference in the plasma levels of digoxin 15 hours after the dose (table I) . This indicates that the excretion rate or metabolization of digoxin was greater for L 2 than for L 1. Since the urinary excretion was increased only about 40% when L 1 was replaced by L 2 (table II) , an increase in metabolization or intestinal excretion is suggested. If the "second peak" observed ( fig. 3 ) represents biliary recycling this indicates that the amount of digoxin excreted in the bile when L 2 was given is important. Because of the rapid absorption of L 2 the level of digoxin in the portal vein and in the liver is higher for L 2 than for L 1 during the first hours after the administration of the drug. The biliary excretion of digoxin must, therefore, be expected to be greater for L 2 than for L 1 as digoxin is eliminated on first order kinetics. A greater biliary excretion of digoxin from the systemic circulation should also be expected for L 2 because of higher plasma levels.
The absorption curves after the dose of 10 mg of L 1 and 0 5 mg of L 2 are almost parallel after constant plasma levels were obtained ( fig. 2 ). This suggests that digoxin in plasma from L 1 and L 2 is handled in the same manner. The difference in metabolization and excretion therefore seems to be a matter of plasma concentration.
The constant plasma levels obtained after ingestion of 10 mg L 1 ought to be higher than after a dose of 0 5 mg L 2. The equal plasma levels 15 hours after administration of 0 5 mg of L 2 and 10 mg of L 1 (group 2, fig. 2 ) seems to conffict with the equal levels 15 hours after the same maintenance dose of L 1 and L 2 given to the patients of group 3 (table I) . This might be explained by characteristics of the digoxin assay, since the concentrations after equilibrium in group 2 are at the lowermost end of the range of sensitivity for the radioimmunoassay. A difference in metabolic clearance rate between digoxin given in a single dose and on a constant maintenance dose is, however, possible.
The shape of the absorption curves for L 1 and L 2 is influenced by a difference in absorption rates. Before the equilibrium the new drug shows a faster rate of fall than the old (fig 2) . This might be partly explained by a more rapid excretion of L 2 because of higher concentration. In addition, the slow absorption of L 1 may continue for several hours and thereby influence the curve for its disappearance rate.
The relation of nausea to peak blood levels observed in five of the subiects in group 1, and the more rapid fall off of The lecithin concentration of amniotic fluid seems to be a sensitive index of fetal lung maturity (Bhagwanani et al., 1972a; Nelson, 1972) . A lecithin concentration of 3-5 mg/100 ml seems to be critical, since values greater than this are associated with normal respiration while lower levels are likely to be associated with R.D.S. in the newborn (Bhagwanani et al., 1972a) . Since the test described by Clements and his colleagues is so much quicker and easier to perform than the most rapid method developed for the biochemical measurement of lecithin in amniotic fluid (Bhagwanani et al., 1972b) The lecithin concentration in amniotic fluid was determined by the procedure previously reported (Bhagwanani et al., 1972b) . This involved chloroform methanol extraction of lipids from amniotic fluid followed by separation of the phospholipids in the extract by chromatography on thin layers of silica gel. 
Discussion
Normal respiration in the neonate depends not only on lung maturation but also on the ability of the lung tissue to synthesize a specific lipoprotein, which effectively lowers surface tension and thereby maintains alveolar stability. This lipoprotein, extracted with saline from fetal lungs at varying stages of gestation, is thought to have the protein moiety conjugated to a variety of phospholipids, the most important of which is supposed to be the dipalmitoyl derivative of lecithin. During development there is preferential synthesis of the dipalmitoyl derivative in the fetal lung. Lung washings from a full-term lamb fetus contain about 10 times more dipalmitoyl lecithin than those from immature fetuses (Brumley et al., 1967a) . The lecithin content of rabbit lung also increases with increasing gestational age and reaches maximum value at term (Gluck et al., 1967) . Surfactant concentration in lung tissue and lung washings in infants dying of hyaline membrane disease is significantly lower than that in infants whose death is due to factors not related to lung function (Avery and Mead, 1959; Adams et al., 1965; Brumley et al., 1967b) .
The lecithin concentration of the fetal lung seems to be reflected in the amniotic fluid. This is supported by the close similarity between the protein, phospholipid, and fatty acid composition of the fetal pulmonary fluid and amniotic fluid (Gluck et al., 1971 ; Scarpelli, 1967) . The surface tension of amniotic fluid, however, is influenced by the presence of various factors including bile salts, salts of free fatty acids, and proteins. At term, unlike fetal pulmonary fluid, it shows high surface tension, and this has been attributed to the inhibitory influence of neutral lipids present (Adams and Fujiwara, 1963; Fujiwara et al., 1964) . Attempts by Fozzard and White (1972) to predict the potential risk of R.D.S. in the newborn by measuring amniotic fluid surface tension by using bubble stability, a modification of Prattle's (1958) 
Summary
Forty-three patients with chronic myeloid leukaemia have been treated with hydroxyurea in order to be subjected to leucopheresis for white celi transfusions. Hydroxyurea decreases leucocytosis when it is administered and the blood granulocyte number increases soon after the drug is stopped. The survival of the patients is not different from the survival of the patients treated with conventional chemotherapy (busulphan, mitobronitol) and it is superior to the survival of patients treated with external radiotherapy or with 2P. Haff of the patients were subjected to splenectomy during first remission for a phase II trial They were not randomized, but the distribution according to age was similar in the two groups. A slight difference appears in favour of splenectomy so far as survival is concerned, but there were three postoperative deaths out of 16 patients. We conclude that a Unite Fred-Sluier, Institut de Cancerologie et d'Immunogenetique Introduction During the past 10 years a few malignant diseases of the haemopoietic and lymphatic systems have been the subject of considerable therapeutic advance. In two of them-acute lymphatic leukaemia (Mathe et al., 1973 ) and Hodgkin's disease (Mathe and Tubiana, 1973) -the possibility of a cure is nearing reality. On the other hand, the prognosis of chronic myeloid leukaemia (C.M.L.) seems to have changed very little. This is all the more disappointing as "myeloid" cells that proliferate at the beginning of the disease are very sensitive to radiotherapy (Bauer and Hartweg, 1962; H. Schoen and R. Bauer, personal communication) and to several drugs which have become available in the past two decades-namely busulphan (Bernard et al., 1955; Galton and Till, 1955), mitobronitol (Sellei and Eckhardt, 1963; Maths et al., 1964) , demecolcine (Moeschlin et al., 1954; Cattan et al., 1966) , piposulfan (N, N14bis-(3-methanesulfonoxypropanoyl) piperazine) (Kenis, 1968) , and hydroxyurea (Fishbern et al., 1964; Cattan et al., 1966) . The explanation for this lack of progress appears to be the inevitable occurrence of a blastic proliferation ("blastic crisis") in patients who do not die from therapeutic or other medical accidents. This means that C.M.L. can be considered as the forerunner of an acute leukaemia. This concept underlies the strategy of the current E.O.R.T.C. "leukemia and hematosarcoma" group C.M.L. therapy protocol, which is designed to test the value of prophylactic antiblastic treatment.
The main object of this study was to settle a logistic and ethical problem which arose when Freireich et al. (1964) and our group (Schwarzenberg et al., 1965) showed that C.M.L. white cell transfusates contain physiologically active leucocytes that can cure agranulocytosis. The question then
